Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center

Melanoma Research
Muhammad Zubair Afzal, Keisuke Shirai

Abstract

Denosumab is a monoclonal antibody against RANK ligand with a role in the prevention of skeletal-related events and is also known to possess antitumor properties. In this retrospective review, we aim to evaluate the synergist effect of a combination therapy with immune checkpoint inhibitors and denosumab in malignant melanoma patients. Patients of 18 years of age or older with a diagnosis of malignant melanoma who have received immune checkpoint inhibitors and denosumab between June 2015 and May 2017 were divided into two cohorts: cohort A (immune checkpoint inhibitors only) and cohort B (immune checkpoint inhibitors and denosumab). Overall survival, progression-free survival, objective response rate, and safety analysis were performed. Stratified analysis based on metastatic (M) status was performed as well. Eleven (29.72%) out of 37 patients received immune checkpoint inhibitors and denosumab combination. Median overall survival in cohort B was 57 months compared with 22.8 months in cohort A and 22 months in M1c patients from cohort A. Median progression-free survival was 4.15 months in cohort B compared with 11.6 months in cohort A and 5.12 months in M1c patients from cohort A. The mean number of distant sites involved in me...Continue Reading

References

Feb 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C M BalchJ R Durant
Sep 29, 1999·Genes & Development·W C DougallJ Schuh
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C M BalchA Morabito
Jun 24, 2003·Immunity·Durbaka V R PrasadChen Dong
Jun 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Giao Q PhanSteven A Rosenberg
Feb 13, 2010·The Lancet Oncology·David ThomasSusie Jun
Feb 20, 2010·Current Pharmaceutical Design·A C HirbeK N Weilbaecher
May 20, 2011·Nature Reviews. Cancer·Katherine N WeilbaecherLaurie K McCauley
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Aug 10, 2011·Current Opinion in Supportive and Palliative Care·Allan Lipton, Ira Jacobs
May 1, 2012·Nature Reviews. Drug Discovery·David L LaceyRoger Dansey
Oct 15, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark J SmythGrant A McArthur
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Sep 22, 2016·Clinical Sarcoma Research·Czar Louie GastonPiotr Rutkowski

❮ Previous
Next ❯

Citations

Jan 25, 2020·Nature Reviews. Clinical Oncology·Jason J Luke, Paolo A Ascierto
May 6, 2019·International Journal of Molecular Sciences·Peter A van DamXuan Bich Trinh
May 24, 2020·Antibodies·Josée Golay, Alain E Andrea
Jun 12, 2019·Cancers·Verena WieserAlain Gustave Zeimet
Oct 18, 2020·International Journal of Molecular Sciences·Aristofania SimatouMichalis V Karamouzis
Nov 10, 2020·Frontiers in Endocrinology·Katerina Trajanoska, Fernando Rivadeneira
Jul 1, 2020·Advanced Science·Xiaofeng DaiKostya Ken Ostrikov
Sep 29, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Quincy S C Chu
Aug 2, 2021·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·André G GouveiaMauricio F Silva
Aug 28, 2021·Cells·Sandra CasimiroLuis Costa

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT03161756

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.